SPEX has formed an exclusive partnership with DigitalHealth.London (DH.L) and MedCity in the UK and developed a scalable investment programme.

We aim to review on average over 1,000 and assess circa 500 of early stage and series A/B companies every year. In the past the NHS calls attracted half of all the flow while the rest was generated via our network. In the future we aim to diversify the source of that flow and attract more and more talents from a variety of countries.

An expert panel of reviewers from the NHS, DH.L, MedCity and our unique advisory board is convened to validate the science and technology behind the shortlisted applicants.

We will also tap into the specific and complementary expertise and network of our partners to further support clinical and technological validation, distribution, and company exits.


SPEX is looking to invest in early stage companies (at Seed stage, Series A and B) to support them in their next phase of growth. Our typical ticket size ranges from £500,000 to £5,000,000.

Our aim is to provide investors with capital appreciation from a diversified portfolio of investments from an early stage. We address an investment gap, sometimes overlooked by institutional and professional investors, to benefit from a diversified portfolio effect and without compromising on due diligence.